Search results
-
Akeso builds up its ivonescimab ambitions again
… 2nd-line NSCLC Ivonescimab + chemo Chemo Data ASCO 2024: ORR 51% vs 35%, PFS 7.1 vs 4.8mo; OS 17.1 vs …
- 09/26/2024 - 12:56 -
ESMO 2024 – combos could be the way forward for CDK2
… Presentation ESMO 2024 ESMO 2024 ASCO 2023 ASCO 2024 Study Ph1 in solid tumours …
- 09/15/2024 - 21:18 -
Replimune goes pivotal in uveal melanoma
… R-, GM-CSF & anti-CTLA-4 Ph1 uveal melanoma data at ASCO 2024; ph2/3 begins Jan 2025 Note: …
- 09/06/2024 - 15:47 -
Regeneron gets another bispecific blow
… x CD28 Solid tumours (+ Libtayo) Ph1/2 data at ASCO 2024: 6% (3/51) ORR in MSS CRC; dose-expansion cohorts …
- 08/23/2024 - 12:44 -
Tissue factor tempts Adcendo
… DAR 3.8 Ph1/2 data in solid tumours presented at ASCO 2024 XNW28012 Evopoint Biosciences None …
- 08/20/2024 - 14:15 -
Another vote of no-confidence in co-stimulated bispecifics
… Ragistomig (ABL503) ABL Bio/ I-Mab Ph1 data at ASCO 2024 MCLA-145 Merus Ph1 Keytruda combo …
- 08/07/2024 - 15:10 -
Boehringer takes on AbbVie in a novel checkpoint
… Huadong Medicine PTPN2 inhibitor Preclinical data at ASCO 2024 Unnamed CD3 PTPN1/2 dual inhibitor …
- 07/30/2024 - 15:58 -
Hookipa hopes for a head and neck fast track
… 37% 53% CR rate 11% 18% Source: ASCO 2024. Data insights Trial …
- 07/25/2024 - 13:39 -
Bristol overtakes Amgen in colorectal
… 2022 based on Krystal-1; confirmatory Krystal-12 data at ASCO 2024 Ph3 Krystal-7, data due 2028 AA 2L Jun 2024 …
- 06/25/2024 - 13:42 -
ASCO 2024 movers – Affimed wins, Caribou loses
ASCO 2024 movers – Affimed wins, Caribou loses … tumbling 26%. Several other stocks moved yesterday too, but ASCO 2024’s most significant biotech beneficiary is …
- 06/10/2024 - 16:07
